.png){kind=icon}
.png){kind=icon}
Return
A Fast Path from Innovation to Safe and Effective Medicine
.png){kind=icon}
OA
AI
P
F
R
E
P
L
I
F
E
A
S
S
DOI：10.1002/cpt.70107.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Consistent progress in medicines development has allowed both for de novo treatment options and for the refinement of existing products that improve effectiveness or reduce harm. Nonetheless, unmet medical needs persist, particularly in rare diseases, pediatrics and underserved populations. The many promises of pharmacological, technological, and regulatory innovation spark new hope for patients and doctors searching for treatments, and it is therefore essential that progress made translates into the availability of new and improved medicines. We here present our vision for accelerating the path from innovation to safe and effective medicines. Our vision is driven by the continued and transparent collaboration between regulators, academia, industry, patients, and healthcare professionals. Through concrete examples and strategic initiatives, we illustrate how the EMA works with stakeholders to support continuous evolution of regulatory science, contribute to patient-focused refinements in evidence generation and medicines assessments, and engage in forward-looking initiatives that monitor and examine innovative developments. The ultimate goal is to future-proof the regulatory ecosystem and ensure that scientific progress translates into meaningful health outcomes.
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
C
IF:
5.5
Papers:
8.6K
Citations:
1.9W
Organization
No organization information available
Cited Papers